INTRODUCTION
============

Asthma in the elderly is a disease of emerging concern. Globally, we are entering an unprecedented era of rapid aging, and the number of elderly people (≥65 years of age) is estimated to double by 2030.[@B1] In the past, asthma was regarded as mostly a childhood disease. However, recent observations indicate that asthma is associated with a substantial epidemiological burden and a distinct pathophysiology in the elderly; the prevalence and incidence of asthma are higher than expected, and the risk factors more complex.[@B2] Socioeconomic costs are also of major concern; elderly patients have disproportionately higher medical demands and poorer outcomes, compared to younger patients.[@B3][@B4]

Despite growing literature on the significance of the disease, how to reduce the burden of asthma effectively in the elderly is not clear.[@B2] Asthma is likely to be underdiagnosed in the elderly, due to poor perception of symptoms and misattribution to other causes.[@B5][@B6] The level of undertreatment of such asthma was as high as 40% in 1993,[@B7] but unexpectedly, it was 33.7% in 2009.[@B8] Moreover, the optimal management of elderly patients with asthma has received little attention, probably because of the complexity of this disease and its being associated with comorbidities and socioeconomic factors.[@B9] Elderly subjects can have multiple chronic diseases,[@B10] and the number of comorbid conditions (termed the \"general comorbidity burden\") is significantly associated with poor asthma outcomes.[@B11][@B12][@B13] Although comorbidities are accepted to play major roles in elderly patients with asthma, the effects of specific comorbidities may have been underappreciated.

In this review, we aim to summarize the literature on the clinical characteristics of elderly patients with asthma, and the associations between asthma and comorbidities. In addition, we discuss the management issues of asthma and comorbidities in the elderly.

Clinical characteristics of asthma in the elderly
-------------------------------------------------

Asthma in the elderly is a mix of childhood- and adult-onset disease and thus a heterogeneous clinical syndrome. The proportion of adult-onset disease among elderly patients is unclear but supposed to be higher than that of childhood-onset disease.[@B14] The clinical characteristics of asthma in the elderly are reported to be complex and considerably distinct from the disease in young adults[@B15]; in particular, a late-onset disease appears to be more severe and less atopic. In our experience with elderly asthma patient cohorts (about 1,000 patients recruited from nine referral hospitals in Korea), more than 90% reported asthma onset after the age of 50 years, and less than 30% had atopy.[@B16] Despite lower atopic associations, elderly patients have comparable degrees of sputum eosinophils or exhaled nitric oxide levels, compared to younger counterparts.[@B17][@B18] In addition, elderly patients have greater small airway involvements, measured by computed tomography and impulse oscillometry.[@B17] Meanwhile, the observed characteristics may vary between studies, depending on definition, sampling methods, or study population. For example, atopic comorbidity was as frequent as 74% among elderly patients (n=566, mean age 71.9 years, mean age of asthma onset 42.3 years) who participated in the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) cohort study in the United States.[@B19] These findings indicate that further clinical characterization should be based on a large-scale unselected population, and that the mechanistic elucidation using clinical samples should accompany detailed characterization of the study participants.

Epidemiology of asthma in the elderly
-------------------------------------

### Prevalence and incidence of asthma in the elderly

Only a few reports have focused primarily on the prevalence and incidence of asthma in the elderly; prevalence is usually reported as a component of general adult surveys. Therefore, the epidemiological study of asthma in the elderly is still at a rudimentary stage. Cross-sectional surveys have found that the prevalence of asthma is 4.5%-12.7% in the elderly.[@B2] Notably, asthma is often more prevalent in the elderly than in younger adults, whether the condition is diagnosed by a self-administered questionnaire alone or a questionnaire together with measures of airway hyperresponsiveness \[AHR\]).[@B20][@B21] Very few longitudinal surveys have explored asthma incidence in the elderly, although a classical study on residents of Rochester, Minnesota, USA (1964-1983) found that the age- and sex-adjusted incidence of the disease was 95/100,000.[@B22] However, a recent French survey of the elderly population, the 3C cohort study (2000-2004), reported that the incidence of asthma was 3.0/1,000 person-years.[@B23]

### Risk factors for asthma in the elderly

Risk factors for the development of asthma in the elderly remain elusive, because longitudinal studies are very few in number. In the 3C cohort study, abdominal obesity and allergic rhinitis were positively associated with asthma.[@B23] In cross-sectional studies, several factors have been associated with current prevalence (usually defined as \"the presence of asthma within the past 12 months\") in the elderly, including AHR,[@B24] smoking,[@B25] rhinitis,[@B26][@B27] or sarcopenic obesity.[@B28] Methacholine AHR exhibits a bimodal age distribution in the general population, increasing in the elderly, and may contribute to accelerated lung function decline and the development of asthma in later stages of life.[@B29][@B30] The association between rhinitis and asthma was also observed in nonatopic subjects.[@B26] However, to the best of our knowledge, no genetic factor influencing asthma in the elderly has yet been reported, unlike the situation with childhood disease. The prevalence of atopy decreases with aging and is inconsistently associated with asthma in the elderly.[@B2] However, IgE-associated asthma in older adults may be attributable to IgE synthesized after sensitization to staphylococcal enterotoxin (SE). SE-IgE sensitization rates do not appear to decrease with age, but rather increase, and are independently associated with a risk of adult-onset asthma.[@B31][@B32]

Such cross-sectional studies have rarely examined the age of asthma onset and afford little information on late-onset asthma in the elderly. Thus, herein, we rely largely on reports on adult-onset asthma, and we speculate that the data may be extrapolated to older adults ([Fig. 1](#F1){ref-type="fig"}). The European Community Respiratory Health Survey (ECRHS) is one of the largest population surveys on adult asthma conducted to date, and longitudinal follow-up has revealed that rhinitis is a strong predictor of asthma during adulthood, irrespective of atopic status.[@B33] This finding has been supported by another recent European population survey, the Global Allergy and Asthma Network of Excellence (GA^2^LEN) study, which found a strong association between chronic rhinosinusitis (CRS) and adult-onset asthma, irrespective of nasal allergy status.[@B34] Regarding this, immune responses to SE may be involved in the relationship[@B31][@B32]; *Staphylococcus aureus* frequently colonizes the human nasal mucosa, and the enterotoxins thereof may provoke CRS and nasal polyp development.[@B35] We suppose that SE-IgE is either a biomarker of CRS and asthma, or an active mediator in the relationships between upper and lower airway disease.

Female sex hormone and obesity may be risk factors for adult-onset asthma, although the effects of hormonal factors have not been directly examined in the elderly. Upon analysis of ECRHS database information on general adults aged 20-44 years, nonallergic asthma was more prevalent in females than in males during 8-10 years of follow-up, associated with a hazard ratio (HR) of 3.51.[@B36] In postmenopausal women (aged 50-70 years) of the E3N cohort, estrogen hormone replacement therapy was positively associated with the risk of *de novo* asthma development (HR 1.54).[@B37] As shown in the 3C study of French elders,[@B23] obesity was a risk factor for adult-onset asthma, particularly in females.[@B14][@B38]

Smoking is another risk factor, although the reported associations have been somewhat inconsistent in adults.[@B39] However, in a recent 16-year follow-up study with a large population cohort (n=46,182), active smoking increased the incidence of adult-onset asthma (HR 4.13 for current active smoking and 1.36 for former active smoking).[@B40] Among patients with allergic rhinitis, smoking is known to increase the risk of adult-onset asthma in a dose-dependent manner.[@B41]

The senile change of the lung is another candidate factor for asthma development in the elderly. Aging is associated with reduced elastic recoil and chest wall compliance,[@B42] which may enhance AHR in the elderly.[@B29] Older age is also associated with accelerated decline in lung function; the estimated rate of decline in forced expiratory volume in 1 second (FEV1) significantly increased with aging (from 12.9 at age 25 to 58.2 mL/year at age 75),[@B43] which was potentiated by smoking.[@B44] In addition, aging is associated with increased amplitude of variability in airway caliber.[@B45][@B46] These findings suggest that the aging process of the lung itself contributes to the development of asthma in the elderly.

### Other comorbid conditions

Several other comorbidities may be potentially important, as elderly subjects have multi-morbidities. In the Korean Longitudinal Study on Health and Aging (KLoSHA) Phase I survey (2005-2006), Korean elders usually had comorbid illnesses in (at least) 3 or 4 organs/systems, defined using the Chronic Illness Rating Scale.[@B10] In a recent study conducted in a referral clinic in Poland, elderly patients with asthma had a mean of 8.[@B4] chronic comorbid diseases, significantly higher than 3.4 in younger adults.[@B47] In a retrospective analysis of the large fourth Korean National Health and Nutrition Survey (KNHANES IV) database, which contains information on 9 major chronic comorbidities, recent wheezing was positively associated with depression (odds ratio \[OR\] 2.08, *P*\<0.001), rhinitis (OR 1.86, *P*=0.035), obesity (OR 1.67, *P*=0.024) and arthritis (OR 1.44, *P*=0.030).[@B48] However, limitations of these studies include case definition and potential type I errors caused by multiple testing, so that more comprehensive studies are required for confirmation.

Depression could be a potential risk factor for asthma in the elderly. A possible psychological aspect of asthma was suggested earlier.[@B49] Current epidemiological evidence shows that asthma and depression are frequently comorbid; the most comprehensive cross-sectional study on this topic to date is the World Mental Health Survey conducted in 17 countries involving 85,088 subjects, which found that adults with asthma were at a significantly increased risk of a depressive disorder (OR 1.6).[@B50] In the elderly, depression may be particularly important in this context because the observed relationship was independent of other conditions.[@B51] The associated mechanisms remain poorly understood. Asthma may impose a significant burden on emotional well-being. Also, the 2 entities have been suggested to share a common pathophysiological pathway.[@B52]

Comorbid factors associated with poor asthma outcomes in the elderly
--------------------------------------------------------------------

In general, the general comorbidity burden is significantly associated with asthma-related quality of life,[@B53] unscheduled asthma care,[@B13] emergency department visit,[@B11] asthma hospitalization,[@B12] or the 30-day fatality rate following asthma hospitalization.[@B54] Here, we briefly describe several comorbid conditions significantly associated with poor asthma outcomes in adults and the elderly ([Table 1](#T1){ref-type="table"}).

In adults, chronic upper airway disease, particularly sinusitis, is very often associated with poor asthma outcomes. In the Severe Asthma Research Program (SARP), 54% of patients with severe asthma had a history of sinusitis (vs 33% of those with mild asthma, and 37% of those with moderate asthma; *P*\<0.001).[@B55] Later cluster analysis of SARP showed that sinus disease was significantly more frequent in patients with the late-onset asthma phenotype (onset age ≥40 years; cluster 3) and the severe asthma phenotype in the oldest subjects (age at enrolment 50 years; cluster 3 and 5) compared to those with early-onset asthma phenotypes.[@B56] In Europe, the risk factors for asthma severity have been examined particularly in patients with adult-onset asthma; nasal polyposis exhibits a strong association with asthma (OR 3.2).[@B57] Although very few studies have been conducted in elderly patients, we recently observed that comorbid CRS is an independent risk factor for frequent asthma exacerbation and disease severity in the elderly (Song, Cho et al., Staphylococcal enterotoxin IgE sensitization in late-onset severe eosinophilic asthma in the elderly; manuscript submitted). Also, SE-IgE sensitization is independently associated with poor outcomes and asthma severity in nonatopic adult patients,[@B58] and with severe eosinophilic asthma in the elderly (Song, Cho et al., manuscript submitted). Notably, atopy was not associated with asthma severity in the cited studies.[@B58]

Obesity has been associated with poor asthma outcomes including a high frequency of symptoms and corticosteroid insensitivity,[@B59][@B60] but may not be directly related to asthma severity. Cluster analyses performed in the United States and Europe have repeatedly identified obese patients as exhibiting a distinct asthma phenotype,[@B56][@B60][@B61] although obesity-related phenotypes are sometimes heterogeneous (not being confined to severe disease).[@B61] Later studies also found that obesity is not associated with asthma severity in adult-onset patients.[@B57] Nevertheless, these findings do not confirm that obesity is not a risk factor, because weight loss interventions improved asthma control-related outcomes in a group of obese patients.[@B62] Thus, obesity may modify asthma, rendering the disease more difficult to treat, presumably by modulating treatment responsiveness, adipokine levels, or innate immune responses.[@B63] In the elderly, comorbid obesity is related to the risk of recent wheezing and higher asthma-related costs.[@B28][@B64]

Smoking is a well-known risk factor for various health conditions, including asthma. A considerable proportion of adult patients with asthma have a smoking history, recently characterized as the \"smoking asthma\" phenotype.[@B65] Several mechanisms have been suggested to explain the adverse consequences of smoking on asthma.[@B66] Clinically, smoking is related to virtually every aspect of asthma control, including poor asthma-related quality of life, poor asthma control, more frequent exacerbation, hospitalization, and asthma-related mortality. Smoking also significantly worsens lung function parameters, leading to persistent airway obstruction and the development of the asthma-chronic obstructive pulmonary disease (COPD) overlap phenotype.[@B66][@B67]

The prevalence of COPD overlap may depend on the definition and study population, but increases with aging, and is reported as frequent as 30% among elderly patients with asthma.[@B68][@B69][@B70] Such patients are at higher risk of poor asthma control, and more frequent exacerbation (prevalence ratio \[PR\] 2.11) and hospitalization (PR 4.11) than the elderly asthma-alone or COPD-alone groups.[@B70][@B71] In our experience, a smoking history (≥31.5 pack-years) and reduced lung function (postbronchodilator FEV1 \<61.1%) are 2 major factors predicting the risk of future asthma exacerbation in the elderly.[@B16]

Depression is a risk factor for poor asthma control and deserves more attention. Depressive symptoms are common among adult patients with active asthma and also associated with poor adherence to asthma therapy after hospital discharge.[@B72] The impact of depression on asthma in the elderly has also been demonstrated in prospective cohort studies; depression is associated with a higher risk of poor medication adherence and poor asthma outcomes, including more exacerbations.[@B73][@B74] Moreover, comorbid depression is significantly associated with a higher 5-year mortality rate among elderly patients with asthma.[@B75]

Several other comorbid conditions may potentially impact asthma in the elderly; these include gastroesophageal reflux disease, aspirin sensitivity, cardiac dysfunction, a history of pulmonary tuberculosis, vocal cord dysfunction, and obstructive sleep apnea. We, however, do not discuss these conditions here.[@B76][@B77][@B78]

Management of comorbidities
---------------------------

Despite the effects of multiple comorbidities on asthma, no study has directly examined the effects of comorbidity control on asthma outcomes in the elderly. The lack of clinical trials may reflect the fact that the elderly have multiple comorbidities that could confound trial outcomes. We searched the Pubmed database using the query (randomized AND trial AND asthma AND \[\"older adults\" OR \"elderly\"\] \[access date: 2015/Jan/12\]) and obtained very few results. Thus, we herein refer to the clinical data from adult patients in general ([Table 2](#T2){ref-type="table"}).

First, treatment of comorbid upper airway diseases may be potentially beneficial, but intranasal corticosteroid pharmacotherapy alone may not be sufficient to improve asthma control. In a previous meta-analysis, compared to a placebo intranasal corticosteroids improved FEV1 and some asthma-specific outcomes in patients with asthma who had comorbid allergic rhinitis. However, the effects were significant only in patients who were not on inhaled or oral corticosteroid therapy.[@B79] In a recent elegant controlled trial, a 24-week course of nasal mometasone given to treat chronic sinonasal disease in patients with inadequately controlled asthma did not significantly improve asthma control.[@B80] In a meta-analysis of the role played by sinus surgery among patients with asthma having comorbid CRS, such surgery had positive effects on the clinical outcomes of asthma,[@B81] although controlled trials are lacking. In a clinical trial of patients with nasal polyps and comorbid asthma, a 16-week course of omalizumab improved both polyp scores and asthma symptoms, suggesting the importance of controlling local IgE which is driven by SE.[@B82]

Second, weight loss interventions may impact asthma. In an open-label, randomized, controlled trial of a 1-year supervised weight reduction program vs standard care in 38 obese patients with asthma (age 18-60 years; body mass index \[BMI\] 30-42 kg/m^2^), the weight reduction program afforded a mean weight loss of 14.5% and improved several asthma outcomes, including lung function, dyspnea score, and the need for rescue medication.[@B83] In obese patients with severe asthma (mean age 42 years; BMI 39 kg/m^2^), a 6-month weight reduction intervention (achieving a mean reduction in weight of 7.5%) improved asthma control and 1 lung function parameter (forced vital capacity).[@B84] These findings provide clinical evidence that weight loss intervention is a potential treatment option in certain patients.

Third, smoking cessation may improve asthma outcomes. In short, complete cessation of smoking for 6 weeks significantly improved the FEV1 (by a mean of 407 mL) and decreased the mean sputum neutrophil percentage (by 29%) in middle-aged adults.[@B85] In a larger randomized trial with 220 patients, a 4-month smoking cessation improved several asthma outcomes in a dose-dependent manner, including the asthma-specific quality of life, the use of β2-agonist rescue therapy, inhaled corticosteroid (ICS) dose, daytime asthma symptoms, and AHR.[@B86] However, multidisciplinary approaches combining counseling with medical therapy are necessary.[@B66]

Finally, despite the frequently reported association of asthma with depression, the literature on the efficacy of depression control on the asthma outcomes of patients of any age is very sparse. In contrast, however, reports on a link between depression and COPD are growing in number.[@B87] In terms of psychological interventions in general, 1 meta-analysis found that cognitive behavioral therapy improves the asthma-related quality of life and that relaxation therapy reduces the use of asthma medication. However, drawing firm conclusions was not possible because of insufficient patient numbers and heterogeneity in study design.[@B88]

Other management issues in the elderly
--------------------------------------

Some practical issues are particularly important in the elderly. In a Korean study on an elderly asthma cohort, poor adherence to ICS therapy and the absence of a caregiver were significant risk factors for exacerbations.[@B73] In an 8-week pilot study on very old patients (mean age 81.6 years) with poorly controlled asthma and comorbidities in Japan, assistance by caregivers when using ICS therapy effectively improved the lung function.[@B89] However, the usual asthma education strategy, which deals only with how to use a peak flowmeter and follow an asthma action plan, failed to improve asthma outcomes in the elderly.[@B90] Thus, adherence is a complex issue in the elderly.

A recent series of studies conducted by Federman et al. in the United States has afforded some novel insights into the management of elderly patients. In an Asthma Beliefs and Literacy in the Elderly (ABLE) cohort, 57.0% of the elderly patients with asthma exhibited poor adherence to daily asthma controller medications.[@B91] This was significantly associated with erroneous beliefs about asthma and treatment thereof, particularly a \"no symptoms, no asthma\" belief (58.7% of the poorly adherent group). Notably, inaccurate beliefs, poor adherence, and the use of incorrect inhaler techniques are more frequent among patients with low levels of health literacy.[@B92][@B93][@B94] This term means \"the degree to which individuals have the capacity to obtain, process and understand basic health information and services to make appropriate health decisions.\"[@B92] Moreover, reduced cognitive function was associated with poor medication behaviors and explained the literacy problem, at least in part.[@B94] Thus, interventions for the elderly must be tailored to the individual levels of health literacy and cognitive function.

Use of an individualized approach is supported by a recent controlled intervention study, which investigated the efficacy of individualized self-regulation program intervention on asthma outcomes in the elderly.[@B95] In this program, patients are assisted by a health educator to identify personal asthma-related problems/barriers and to develop plans to achieve asthma-specific goals. The intervention runs for 6 weeks, and effectively improves asthma-related quality of life, asthma control, and unscheduled health care utilization. The effects are maintained for about 1 year.

Continuity of care is another important issue in the elderly. In an analysis of the Korea National Health Insurance Claims database, a higher level of continuity of care was significantly associated with a lower risk of hospitalization of and reduced medical costs for elderly persons with asthma.[@B96] Collectively, these findings indicate that multidisciplinary approaches are needed to manage asthma in the elderly.

The general rules of pharmacotherapy for the elderly are not different from those for general adult patients. However, the treatment response needs to be carefully monitored because elderly patients may have discordant correlations between changes in symptoms and lung function.[@B97] In addition, side effects, polypharmacy, and drug interactions are major concerns in the elderly.[@B2] Concomitant oral corticosteroids may increase the risk of hypothalamic-pituitary-adrenal axis suppression in elderly patients on long-term ICS therapy,[@B98] and inhaled β-agonists may induce tremor or tachycardia in susceptible patients. Inhaled long-acting anticholinergics may be a good option if bronchodilating and possible anti-inflammatory effects are sought,[@B99] considering the age-related reduction in lung function and the frequent overlap between asthma and COPD in the elderly.[@B68][@B69][@B70] Theophylline levels must be monitored regularly, and possible drug interactions (upon concomitant treatment) must be carefully considered.[@B2] Leukotriene receptor antagonists are usually well-tolerated, but the efficacy thereof in the elderly warrants further investigation.[@B100]

CONCLUSIONS
===========

Many challenges in management of asthma in the elderly are apparent. Not only asthma management issues, but also comorbid conditions impose significant burdens on the elderly ([Fig. 2](#F2){ref-type="fig"}). Despite the significance of comorbidities, very little clinical evidence is available on the efficacy of controlling comorbidities in the elderly; previous trials have rarely focused on elderly patients. Several other practical issues must be considered, including the role of a caregiver, health literacy, and cognitive functioning. Thus, management of asthma in the elderly should be multifaceted, and the recent growth in reports on elderly health is encouraging. We anticipate that an evidence-based management strategy for asthma and multiple comorbidities in the elderly will be forthcoming.
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![Schematic presentation for the epidemiology of asthma in the elderly. Lines indicate the aged-related changes in the prevalence; gray line, childhood-onset asthma; blue line, airway hyperresponsiveness; and red line, late-onset adult asthma. Adult asthma prevalence was depicted based on previous publications.[@B25][@B31]\
AHR, airway hyperresponsiveness; SE-IgE, staphylococcal enterotoxin IgE.](aair-7-431-g001){#F1}

![Management issues of asthma in the elderly. Arrows with lines indicate the hypothetical relationships between aging, asthma, comorbidity, and other issues. Red line, effects of comorbidity; blue line, effects of aging-related changes; and dotted black line, effects of other management issues.](aair-7-431-g002){#F2}

###### Summary of comorbid conditions associated with poor asthma outcomes in adults and the elderly

![](aair-7-431-i001)

  Comorbid condition                                   Outcomes of asthma
  ---------------------------------------------------- -----------------------------------------------
  General comorbidity burden                           Impaired asthma-related quality of life[@B53]
  Unscheduled asthma care[@B13]                        
  Emergency department visit[@B11]                     
  Frequent hospitalization[@B12]                       
  30-day fatality after asthma hospitalization[@B54]   
  Rhinosinusitis and/or nasal polyp                    Severity[@B55][@B56][@B57]
  SE-IgE sensitization                                 Severity[@B58]
  Obesity                                              Symptom frequency and activity[@B28][@B60]
  Asthma-related costs[@B64]                           
  Severity (controversial)[@B57][@B61]                 
  Smoking                                              Asthma-related quality of life[@B66]
  Poor asthma control[@B66]                            
  Frequent exacerbation[@B16][@B66]                    
  Frequent hospitalization[@B66]                       
  Asthma-related mortality[@B66]                       
  Fixed airway obstruction[@B66][@B67]                 
  COPD overlap, or reduced FEV1                        Poor asthma control[@B70]
  Frequent exacerbation[@B16]                          
  Depression                                           Poor medication adherence[@B72]
  Frequent exacerbation[@B73]                          

SE-IgE, staphylococcal enterotoxin IgE; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.

###### Summary of major clinical trials on the effects of controlling comorbidity on asthma outcomes in adults

![](aair-7-431-i002)

  First author (year)^ref^        Participants                                                                                                              Study design and intervention                                                                                                                                                      Main findings on the intervention
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dixon (2014)[@B80]              237 adults and 151 children with chronic sinonasal disease and inadequately controlled asthma (median age 27 years old)   24-week randomized double-blind placebo-controlled trial, intranasal mometasone versus placebo                                                                                     In adults, there was a small difference in asthma symptoms and in nasal symptoms, but no difference in asthma quality of life, lung function, or episodes of poorly controlled asthma.
  Gevaert (2012)[@B82]            24 patients with nasal polyps and asthma (median age around 50 years old)                                                 16-week randomized double-blind placebo-controlled trial, omalizumab versus placebo                                                                                                There was a significant decrease in endoscopic polyp scores and Lund-Mackay score, and also in upper and lower airway symptoms and quality of life scores.
  Stenius-Aarniala (2000)[@B83]   38 patients with asthma and obesity (BMI 30-42 kg/m^2^, age 18-60 years old)                                              1-year randomized open-labelled controlled trial, supervised weight reduction program with 8-week very low energy diet versus standard care                                        There were significant reduction in body weight (14.5%) and also improvements in lung function parameters (FEV1 and FVC), dyspnea scale, rescue medication use, and exacerbation frequency.
  Dias-Júnior (2014)[@B84]        33 patients with severe asthma and obesity (mean BMI 39 kg/m^2^, mean age 42 years old)                                   6-month randomized open-labelled controlled trial, weight loss program (low caloric intake, sibutramine 10 mg per day, and orlistat maximum 120 mg per day) versus standard care   There were significant reduction in body weight (7.5%) and also improvements in asthma control and FVC.
  Chaudhuri (2006)[@B85]          32 smokers with asthma (mean age 47 years old, 36 pack-year)                                                              6-week, non-randomized open controlled trial, smoking cessation                                                                                                                    There were significant improvement in FEV1 and reduction in sputum neutrophils.
  Tønnesen (2005)[@B86]           220 smokers with asthma (mean age 35 years old, 19 pack-year)                                                             4-month, randomized open controlled trial, complete smoking cessation versus smoking reduction to fewer than seven cigarettes/day versus continuation of usual smoking             There were significant improvements in asthma-specific quality of life score, reductions in self-reported day and night use of rescue β2-agonists, doses of inhaled corticosteroids, in daytime asthma symptoms, and in bronchial hyperreactivity.

BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
